219 related articles for article (PubMed ID: 33546774)
21. Molecular and Genomic Landscape of Peripheral T-Cell Lymphoma.
Iqbal J; Amador C; McKeithan TW; Chan WC
Cancer Treat Res; 2019; 176():31-68. PubMed ID: 30596212
[TBL] [Abstract][Full Text] [Related]
22. Angioimmunoblastic T-cell lymphoma in Taiwan reveals worse progression-free survival for
Hsu YT; Wang YC; Chen RY; Hung LY; Li SS; Yen CC; Chen TY; Medeiros LJ; Chang KC
Leuk Lymphoma; 2020 May; 61(5):1108-1118. PubMed ID: 31870198
[TBL] [Abstract][Full Text] [Related]
23. Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma.
Zhang P; Zhang M
Clin Epigenetics; 2020 Nov; 12(1):169. PubMed ID: 33160401
[TBL] [Abstract][Full Text] [Related]
24. [Analysis of clinicopathological and molecular abnormalities of angioimmunoblastic T-cell lymphoma].
Shi YF; Wang HJ; Liu WP; Mi L; Long MP; Liu YF; Lai YM; Zhou LX; Diao XT; Li XH
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Jun; 55(3):521-529. PubMed ID: 37291929
[TBL] [Abstract][Full Text] [Related]
25. A targeted mutational landscape of angioimmunoblastic T-cell lymphoma.
Odejide O; Weigert O; Lane AA; Toscano D; Lunning MA; Kopp N; Kim S; van Bodegom D; Bolla S; Schatz JH; Teruya-Feldstein J; Hochberg E; Louissaint A; Dorfman D; Stevenson K; Rodig SJ; Piccaluga PP; Jacobsen E; Pileri SA; Harris NL; Ferrero S; Inghirami G; Horwitz SM; Weinstock DM
Blood; 2014 Feb; 123(9):1293-6. PubMed ID: 24345752
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic and prognostic implications of tumor expression of the GATA-3 gene in nodal peripheral T-cell lymphoma (nPTCL): Retrospective data from a Latin American cohort.
de Pádua Covas Lage LA; Brito CV; Levy D; Culler HF; Freitas Couto SC; de Oliveira LBA; Nogueira Zerbini MC; Rocha V; Pereira J
Leuk Res; 2022 Mar; 114():106794. PubMed ID: 35131666
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathological features of programmed cell death-1 and programmed cell death-ligand-1 expression in the tumor cells and tumor microenvironment of angioimmunoblastic T cell lymphoma and peripheral T cell lymphoma not otherwise specified.
Kim S; Kwon D; Koh J; Nam SJ; Kim YA; Kim TM; Kim CW; Jeon YK
Virchows Arch; 2020 Jul; 477(1):131-142. PubMed ID: 32170448
[TBL] [Abstract][Full Text] [Related]
28. Angioimmunoblastic T-cell lymphoma in Taiwan shows a frequent gain of ITK gene.
Liang PI; Chang ST; Lin MY; Hsieh YC; Chu PY; Chen CJ; Lin KJ; Jung YC; Hwang WS; Huang WT; Chang WC; Ye H; Chuang SS
Int J Clin Exp Pathol; 2014; 7(9):6097-107. PubMed ID: 25337257
[TBL] [Abstract][Full Text] [Related]
29. [Mutation characteristics of angioimmunoblastic T-cell lymphoma: an analysis of 75 cases].
Shen X; Yi HM; Li AQ; Ouyang BS; Dong L; Wang CF
Zhonghua Bing Li Xue Za Zhi; 2024 Jan; 53(1):29-33. PubMed ID: 38178743
[No Abstract] [Full Text] [Related]
30. Clinicopathological implications of immunohistochemical expression of TBX21, CXCR3, GATA3, CCR4, and TCF1 in nodal follicular helper T-cell lymphoma and peripheral T-cell lymphoma, not otherwise specified.
Han B; Lim S; Yim J; Song YK; Koh J; Kim S; Lee C; Kim YA; Jeon YK
J Pathol Transl Med; 2024 Mar; 58(2):59-71. PubMed ID: 38247153
[TBL] [Abstract][Full Text] [Related]
31. [Current standard in diagnostic and therapy of peripheral T-cell lymphoma].
Hopfinger G; Staber P
Dtsch Med Wochenschr; 2019 Oct; 144(20):1400-1404. PubMed ID: 31594013
[TBL] [Abstract][Full Text] [Related]
32. Large cell morphology, CMYC+ tumour cells, and PD-1+ tumour cell/intense PD-L1+ cell reactions are important prognostic factors in nodal peripheral T-cell lymphomas with T follicular helper markers.
Mihashi Y; Kimura S; Iwasaki H; Oshiro Y; Takamatsu Y; Kawauchi S; Shimajiri S; Ishizuka K; Takeshita M
Diagn Pathol; 2021 Nov; 16(1):101. PubMed ID: 34742294
[TBL] [Abstract][Full Text] [Related]
33. Targeting
Hu L; Zhang X; Li H; Lin S; Zang S
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428791
[TBL] [Abstract][Full Text] [Related]
34. Detection of the G17V RHOA mutation in angioimmunoblastic T-cell lymphoma and related lymphomas using quantitative allele-specific PCR.
Nakamoto-Matsubara R; Sakata-Yanagimoto M; Enami T; Yoshida K; Yanagimoto S; Shiozawa Y; Nanmoku T; Satomi K; Muto H; Obara N; Kato T; Kurita N; Yokoyama Y; Izutsu K; Ota Y; Sanada M; Shimizu S; Komeno T; Sato Y; Ito T; Kitabayashi I; Takeuchi K; Nakamura N; Ogawa S; Chiba S
PLoS One; 2014; 9(10):e109714. PubMed ID: 25310466
[TBL] [Abstract][Full Text] [Related]
35. DNMT3A
Zheng J; Wang Z; Pan X; Zhang Z; Li H; Deng X; Liu P; Zhang Q; Na F; Chen C; Niu T; Liu Y
Oncogene; 2023 Jun; 42(23):1940-1950. PubMed ID: 37127775
[TBL] [Abstract][Full Text] [Related]
36. TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy.
Johnson WT; Ganesan N; Epstein-Peterson ZD; Moskowitz AJ; Stuver RN; Maccaro CR; Galasso N; Chang T; Khan N; Aypar U; Lewis NE; Zelenetz AD; Palomba ML; Matasar MJ; Noy A; Hamilton AM; Hamlin P; Caron PC; Straus DJ; Intlekofer AM; Lee Batlevi C; Kumar A; Owens CN; Sauter CS; Falchi L; Lue JK; Vardhana SA; Salles G; Dogan A; Schultz ND; Arcila ME; Horwitz SM
Blood Adv; 2023 Sep; 7(17):5172-5186. PubMed ID: 37078708
[TBL] [Abstract][Full Text] [Related]
37. DNMT3A mutations define a unique biological and prognostic subgroup associated with cytotoxic T cells in PTCL-NOS.
Herek TA; Bouska A; Lone W; Sharma S; Amador C; Heavican TB; Li Y; Wei Q; Jochum D; Greiner TC; Smith L; Pileri S; Feldman AL; Rosenwald A; Ott G; Lim ST; Ong CK; Song J; Jaffe ES; Wang GG; Staudt L; Rimsza LM; Vose J; d'Amore F; Weisenburger DD; Chan WC; Iqbal J
Blood; 2022 Sep; 140(11):1278-1290. PubMed ID: 35639959
[TBL] [Abstract][Full Text] [Related]
38. TET2 mutations in B cells of patients affected by angioimmunoblastic T-cell lymphoma.
Schwartz FH; Cai Q; Fellmann E; Hartmann S; Mäyränpää MI; Karjalainen-Lindsberg ML; Sundström C; Scholtysik R; Hansmann ML; Küppers R
J Pathol; 2017 Jun; 242(2):129-133. PubMed ID: 28337768
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic Aberrations and Targets in Peripheral T-Cell Lymphoma.
Atallah-Yunes SA; Robertson MJ; Davé UP
Clin Lymphoma Myeloma Leuk; 2022 Sep; 22(9):659-665. PubMed ID: 35577752
[TBL] [Abstract][Full Text] [Related]
40. Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma.
Heavican TB; Bouska A; Yu J; Lone W; Amador C; Gong Q; Zhang W; Li Y; Dave BJ; Nairismägi ML; Greiner TC; Vose J; Weisenburger DD; Lachel C; Wang C; Fu K; Stevens JM; Lim ST; Ong CK; Gascoyne RD; Missiaglia E; Lemonnier F; Haioun C; Hartmann S; Pedersen MB; Laginestra MA; Wilcox RA; Teh BT; Yoshida N; Ohshima K; Seto M; Rosenwald A; Ott G; Campo E; Rimsza LM; Jaffe ES; Braziel RM; d'Amore F; Inghirami G; Bertoni F; de Leval L; Gaulard P; Staudt LM; McKeithan TW; Pileri S; Chan WC; Iqbal J
Blood; 2019 Apr; 133(15):1664-1676. PubMed ID: 30782609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
